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Abstract: Starting from 2,3-bis(tetradecyloxy)propan-1-amine (1), the synthesis of the 
target compound 1-[2,3-bis(tetradecyloxy)propyl]-3-[2-(piperazin-1-yl)ethyl]urea (2) is 
reported. The title compound was characterized by 1H-NMR, 13C-NMR and ESI/MS analysis.  
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1. Introduction 
Non-viral vectors have emerged in the last decade as a promising approach for the treatment of 
diseases involving DNA and RNA molecules. [1] There is a good number of examples in which non-viral 
vectors have been linked with nucleic acids by using covalent approaches or combined with each other 
by optimized formulations. These two approaches have allowed the synthesis of the anticipated nucleic 
acid conjugates or complexes, respectively. Cationic lipids [2], dendrimers [3], cell-penetrating 
peptides [4] or polymers [5] have become the most common units used to improve the nucleic acids 
efficacy in cellular transfection processes. Despite the existence of an arsenal of non-viral vectors, the 
use of cationic lipids remains one of the most used transfecting agents due to their simple preparation, 
biodegradability and their wide use in clinical trials. 
The pioneering work carried out by Felgner et al. in 1987 [6] demonstrated how a synthetic 
glycerol-based cationic lipid (DOTMA) was able to interact with DNA and impart cellular uptake, 
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leading to the expected lipid-DNA complex fusion with the plasma membrane. Since then, a wide 
number of cationic lipids has been reported and tested as potential non-viral carriers [7]. 
As a general structure, synthetic glycerol-based cationic lipids are mostly made of a glycerol 
backbone which contains two points of diversity: a hydrocarbonated alkyl chain and a cationic head 
group (Figure 1). This has led to the synthesis of novel cationic lipids series in a combinatorial fashion 
in order to optimize the initial “lead compound.” Examples of these combinatorial libraries have been 
reported [8,9]. 
Recently, we reported the ability of a synthetic amino lipid (1) to interact with plasmid DNA and 
impart efficiently cellular uptake. These studies were carried out both in vitro and in vivo, obtaining 
promising transfection results (Figure 1A) [10,11]. This transfecting agent contained a double-tailed 
hydrocarbonated alkyl chain with ether linkages, a glycerol backbone and a primary amino group as a 
cationic head. As part of our ongoing efforts in the synthesis of novel cationic lipids to improve the 
cellular uptake of genetic materials, we herein report the synthesis of 1-[2,3-bis(tetradecyloxy)propyl]-
3-[2-(piperazin-1-yl)ethyl]urea (2), a glycerol-based cationic lipid which contains two hydrocarbonated 
alkyl ether chains of fourteen atoms of carbon and a piperazine moiety that would act as a cationic 
head. The covalent linkage between the hydrophobic and the hydrophilic part was accomplished by 
forming the anticipated urea derivative (Figure 1B). 
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Figure 1. Di(O-alkyl)glycerol-based cationic lipids general structure. (A) Compound (1) 
was successfully evaluated as a transfecting agent; (B) The title compound (2) was 
designed as a second-generation molecule from our “lead compound 1”. 
2. Results and Discussion  
The synthesis of the title cationic lipid (2) is displayed in Scheme 1. As previously reported,  
N-Boc-protected diol (3) was used as a starting material for the synthesis of 2,3-bis(tetradecyloxy) 
propan-1-amine (1). Compound (3) was subjected to alkylation by phase-transfer catalyst under basic 
conditions at 60 °C followed by a Boc-deprotection reaction under acidic conditions to achieve the 
anticipated amino lipid compound (1) in quantitative yield [10]. 
The introduction of the piperazine derivative (4) and the synthesis of the title compound (2) was 
carried out following two consecutive reactions: Firstly, the conversion of the corresponding primary 
amine (1) to the intermediate 4-nitrophenyl chloroformate at room temperature; and secondly, the 
displacement of the 4-nitrophenyl moiety promoted by the protected N-Boc-piperazine amino 
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derivative (4). These reactions afforded the anticipated protected urea compound after purifying by 
flash chromatography (CH2Cl2:MeOH 6%) in good yield (81%). Finally, the N-Boc protecting group 
was conveniently removed by treatment with 10% trifluoroacetic acid (TFA) in an organic solvent like 
dichloromethane (CH2Cl2) at room temperature with high yields (85%). Following treatment with 
TFA, the amine salt was properly liberated with polymer-supported carbonate base (Amberlite IRA 
900 NaCO3− form) in ethyl acetate at room temperature [12]. This protocol generated the expected 
compound (2) in good yield (85%). 
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Reagents and conditions: a. 4-nitrophenyl chloroformate (1.5 eq), CH2Cl2:THF (1:1), DIEA (1.5 eq), r.t., 5 h; 
b. 4 (1.0 eq), TEA (1.0 eq), DMF, r.t., overnight; c. 10% TFA:CH2Cl2, r.t., 1 h; d. Polymer-supported 
carbonate (10.0 eq), AcOEt, r.t., 1 h. 
Scheme 1. Synthesis of the title compound 2. 
3. Experimental Section 
3.1. General Methods 
All reagents, dry solvents and chemicals were purchased from Sigma-Aldrich (Tres Cantos, Madrid, 
Spain) and were used as received without further purification. All reactions were carried out in  
oven-dried glassware under inert atmosphere of argon. Analytical thin layer chromatography (TLC) 
was done on E. Merck silica gel 60 F254 plates (Merck, Darmstadt, Germany), visualized by UV and 
stained with phosphomolybdic acid. Flash chromatography was carried out on silica gel SDS  
0.063–0.2 mm/70–230 mesh (Solvent Documentation Syntheses, Peypin, France). 1H- and 13C-NMR 
spectra were recorded at 25 °C on a Varian Mercury 400 MHz spectrometer (Varian Inc., Palo Alto, 
CA, USA). Tetramethylsilane (TMS) was used as an internal reference (0 ppm) for 1H spectra recorded 
in CDCl3 and the residual signal of the solvent (77.16 ppm) for 13C spectra. Chemical shifts were 
reported in part per million (ppm) in the δ scale, coupling constants (J) in Hz and multiplicity as 
follows: bs (broad singlet), m (multiplet), t (triplet). Electrospray ionization mass spectra (ESI-MS) 
were recorded on a Micromass ZQ instrument (Waters Corporation, Milford, MA, USA) with single 
quadrupole detector coupled to an HPLC, and high-resolution (HR) ESI-MS on an Agilent 1100 
LC/MS-TOF instrument (Agilent Technologies, Santa Clara, CA, USA). 
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3.2. 1-[2,3-Bis(tetradecyloxy)propyl]-3-[2-(piperazin-1-yl)ethyl]urea (2) 
(a) 2,3-bis(tetradecyloxy)propan-1-amine (1) (25 mg; 0.052 mmol) was dissolved in a mixture of 
anhydrous CH2Cl2 and THF (1:1) (total volume: 1.0 mL). Then, DIEA (1.5 eq) and p-nitrophenyl 
chloroformate (15.7 mg; 0.078 mmol) were carefully added at room temperature. The mixture was 
stirred at room temperature for 5 h. The solvent was reduced in vacuo obtaining a yellow oil. The 
crude was used without further purification in the next reaction step. 
(b) The resulting product (30 mg; 0.046 mmol) was dissolved in anhydrous DMF (1.0 mL) and the 
N-Boc-protected piperazine amine derivative (4) was added dropwise together with TEA (1.0 eq). The 
resulting mixture was stirred overnight at room temperature. The solvent was removed under reduced 
pressure and purified by flash chromatography (CH2Cl2:MeOH 6%). A yellowish oil was obtained (81%). 
(c) Finally, the resulting compound (27.5 mg; 0.037 mmol) was dissolved in a mixture of 10% TFA 
in CH2Cl2 (1.0 mL). The reaction was stirred at room temperature for 1 h. The solvent was reduced in 
vacuo and the anticipated trifluoroacetate salt was used without further purification. The dried crude 
was dissolved in AcOEt (2.0 mL) and polymer-supported carbonate base (Amberlite IRA 900 NaCO3− 
form) (10.0 eq) was added. The mixture was stirred for 1 h at room temperature (until pH of the 
organic layer was basic). Finally, the resin was filtered off and the filtrate was removed under vacuum 
obtaining the expected cationic lipid derivative (2) (20.1 mg; 0.031 mmol) with good yields (85%).  
1H-NMR (400 MHz, CDCl3) δ (ppm) 5.54 (bs, NH-CO), 5.26 (bs, NH-CO), 3.52 (m, 1H), 3.44 (m, 
8H), 3.26 (m, 2H; -N-CH2-CH2-NH-), 3.18 (m, 4H; piperazine ring), 2.78 (m, 4H; piperazine ring), 
2.60 (m, 2H; -N-CH2-CH2-NH-), 1.51 (m, 4H; 2 CH2 alkyl chain), 1.23 (m, 44H; alkyl chain), 0.85 (t, 
J = 6.6 Hz; 6H; 2 CH3-CH2). 
13C-NMR (125 MHz, CDCl3) δ (ppm) 161.8 (CO), 161.4, 77.6 (CH-O), 71.8 (CH2-O), 70.4 (CH2-O), 
58.1 (CH2-O), 48.6 (CH2-N), 40.8 (CH2-N), 40.7 (HO-CH-CH2-N), 34.8 (CH2-CH2-Pip), 31.9 (CH2-CH2-N), 
29.9, 29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 28.1, 26.0, 25.9, 22.6 (alkyl chain), 14.0 (CH3-C). 
HRMS (ESI+) m/z calcd for C38H79N4O3 [M + H]+ 639.6147 found 639.6147. 
1H-NMR, 13C-NMR and ESI-MS spectra for the title compound 2 are available in the 
Supplementary Information. 
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